Cero Therapeutics Holdings Inc. (CERO)

Overview

CERo Therapeutics Holdings, Inc. is a pioneering immunotherapy company with a focus on the development of engineered T cell therapeutics for cancer treatment. Based in South San Francisco, California, the company leverages cutting-edge technology to advance its mission of providing effective cancer therapies. Its efforts are primarily directed towards hematologic malignancies, employing innovative strategies to target and neutralize cancer cells.

Products and Services

• Engineered T Cell Therapeutics

  CERo Therapeutics is at the forefront of developing engineered T cell therapies, a revolutionary approach to cancer treatment. These therapies harness the power of the body's immune system, specifically T cells, which are genetically modified to better recognize and destroy cancer cells. The company's focus on hematologic malignancies involves creating T cells that can effectively target markers or signals unique to certain cancer cells, offering a more precise and potent treatment option compared to traditional methods.

• Targeting the Eat Me Signal

  The lead program of CERo Therapeutics involves targeting an "Eat Me" signal that is upregulated on B cell and myeloid tumors. This unique approach focuses on exploiting a natural process by which the immune system distinguishes unhealthy or malignant cells from healthy ones. By engineering T cells to recognize this signal, CERo aims to enhance the immune system's ability to attack and eliminate cancer cells, offering a promising strategy for patients suffering from specific types of blood cancers.